Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

21 Jan 2010 07:00

RNS Number : 8912F
ViaLogy PLC
21 January 2010
 



VIALOGY PLC

TRADING STATEMENT

 

PERMIAN BASIN WELL SUCCESS IS TECHNOLOGY MILESTONE

--- "A-Level" stress test for QuantumRD

--- Broad oil patch application seen for technology

London, January 21, 2010, ViaLogy PLC (LSE: VIY). ViaLogy announces that, under contract to its client Fasken Oil and Ranch, Ltd. of Midland, Texas, the first successful well has been drilled and is in the process of being completed on their Andrews County prospect. The leading privately-held Exploration and Production company agreed to collaborate with ViaLogy to use its proprietary technology, QuantumRD®, to analyze 3-D and multi-component seismic data, well logs and geological records to locate well sites in a 10 square mile Permian Basin acreage block. 

Drilling at the ViaLogy-designated location took three weeks and reached a prescribed total depth of 11,241 feet. Initial well log analysis shows potential for multiple zones that could be high-graded, highlighted by a net interval of over 50' feet of significant porosity in the Strawn formation alone. Strawn limestone porosities are typically very low. For this formation to be economically viable porosity must reach at least 4%. One of ViaLogy's key challenges was to locate this porosity and to quantify its aerial extent. Strawn targets are typically found at depths greater than 9000 feet and with 3% porosities or less are deemed non-productive. The QuantumRD technology succeeded in locating large continuous zones of 6% plus porosity, a major achievement. Detailed volumetrics will be computed in the near-term.

 

All the more significant is the fact that over the last 50 years only three of 18 attempted Strawn wells in the prospect area showed production. Of the 15 remaining, seven were completed to produce oil from shallower zones in the Wolfcamp formations, no porosity having been found in the Strawn. Eight were declared as dry holes. Additionally, preliminary work shows that the ViaLogy technology can increase the ability to detect hydrocarbon presence directly using seismic data to accurately characterize Wolfcamp carbonates.

 

Participating in the Fasken prospect analysis as an advisor is Dr. Bob Hardage of the University of Texas' Bureau of Economic Geology (UT BEG), widely acknowledged as one of America's leading technology centers for hydrocarbon exploration.

 

Reviewing the drilling results, Dr. Hardage commented, "The prediction of a higher porosity zone within the Strawn is impressive and appears to validate the advantages of the weak signal processing capability underlying QuantumRD to see subtle changes in the data. Porosity variations in Strawn stratigraphy are difficult to amplify using conventional geophysical processing." Despite advances in 3D seismic acquisition and processing, the exploration industry has faced a major challenge in characterizing porosity in complex stratigraphic formations known to exhibit fracture and structural changes below acquisition resolution.

 

According to the client firm's Chief Geophysicist, "We are impressed by the accuracy of ViaLogy's predictions, and especially pleased with QuantumRD's capability to use seismic data to accurately detect porosity zones within the Strawn formation. This was a very difficult problem. Significant undeveloped acreage still exists in the Midland Basin. The introduction of a technology that can characterize porosity in deeper carbonate intervals could make a substantial difference."

He added, "This well demonstrated to us QuantumRD's potential to determine drilling locations based on our exploration criteria. We look forward to working closely with ViaLogy to discover and develop deeper formations on our acreage including the Strawn, Devonian, and Ellenburger"

ViaLogy CEO Robert Dean said, "We couldn't be more pleased with our performance. The only real test for an oil-finding technology is: Can it find oil in the field - not in the laboratory? This is what we are focused on and we're looking forward to proving our technology in the field. Our core patented technology, a technique for the injection of noise to enhance the signal to noise ratios seen in seismic data, allows us to extract more information from the data - and to identify sub-surface characteristics more effectively than other techniques. This challenge was to locate oil and gas in formations that had often eluded other efforts and available techniques. This has been a great partnership that will allow us to enhance and improve the ability of E&P companies to produce from Wolfberry, Strawn and deeper formations."

ViaLogy PLC

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) 

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce) 

Mark Percy +44 (0) 20-7107-8000 

About ViaLogy: Network Centric Signal Processing 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results,

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPGUUUGUPUPPU
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.